M Allison Wolf1, Pier Paolo Claudio. 1. a McKown Translational Genomic Research Institute and Department of Biochemistry and Microbiology, Joan C. Edwards School of Medicine , Marshall University, Huntington , West Virginia , USA.
Abstract
Metastasis and chemoresistance represent two detrimental events that greatly hinder the outcome for those suffering with head and neck squamous cell carcinoma (HNSCC). Herein, we investigated benzyl isothiocyanate's (BITC) ability to inhibit HNSCC migration and invasion and enhance chemotherapy. Our data suggests that treatment with BITC 1) induced significant reductions in the viability of multiple HNSCC cell lines tested (HN12, HN8, and HN30) after 24 and 48 h, 2) decreased migration and invasion of the HN12 cells in a dose dependent manner, and 3) inhibited expression and altered localization of the epithelial-mesenchymal transition (EMT) marker, vimentin. We also observed that a pretreatment of BITC followed by cisplatin treatment 1) induced a greater decrease in HN12, HN30, and HN8 cell viability and total cell count than either treatment alone and 2) significantly increased apoptosis when compared to either treatment alone. Taken together these data suggest that BITC has the capacity to inhibit processes involved in metastasis and enhance the effectiveness of chemotherapy. Consequently, the results indicate that further investigation, including in vivo studies, are warranted.
class="Disease">Metastasis and chemoresistance reclass="Chemical">present two detrimental events that greatly hinder the outcome for those suffering with class="Chemical">pan class="Disease">head and neck squamous cell carcinoma (HNSCC). Herein, we investigated benzyl isothiocyanate's (BITC) ability to inhibit HNSCC migration and invasion and enhance chemotherapy. Our data suggests that treatment with BITC 1) induced significant reductions in the viability of multiple HNSCC cell lines tested (HN12, HN8, and HN30) after 24 and 48 h, 2) decreased migration and invasion of the HN12 cells in a dose dependent manner, and 3) inhibited expression and altered localization of the epithelial-mesenchymal transition (EMT) marker, vimentin. We also observed that a pretreatment of BITC followed by cisplatin treatment 1) induced a greater decrease in HN12, HN30, and HN8 cell viability and total cell count than either treatment alone and 2) significantly increased apoptosis when compared to either treatment alone. Taken together these data suggest that BITC has the capacity to inhibit processes involved in metastasis and enhance the effectiveness of chemotherapy. Consequently, the results indicate that further investigation, including in vivo studies, are warranted.
Authors: George H Yoo; Marie P Piechocki; John F Ensley; Tam Nguyen; Jeffery Oliver; Hong Meng; Danny Kewson; Terry Y Shibuya; Fulvio Lonardo; Michael A Tainsky Journal: Clin Cancer Res Date: 2002-12 Impact factor: 12.531
Authors: Monique M Nijkamp; Paul N Span; Ilse J Hoogsteen; Albert J van der Kogel; Johannes H A M Kaanders; Johan Bussink Journal: Radiother Oncol Date: 2011-06-22 Impact factor: 6.280
Authors: Panomwat Amornphimoltham; Vyomesh Patel; Akrit Sodhi; Nikolaos G Nikitakis; John J Sauk; Edward A Sausville; Alfredo A Molinolo; J Silvio Gutkind Journal: Cancer Res Date: 2005-11-01 Impact factor: 12.701
Authors: Brian Hutzen; William Willis; Sarah Jones; Ling Cen; Stephanie Deangelis; Beng Fuh; Jiayuh Lin Journal: Cancer Cell Int Date: 2009-08-27 Impact factor: 5.722